Why Cassava Sciences Shares Are Moving Today

Cassava Sciences Inc SAVA shares are trading higher by 11.2% at $88.50 after the company highlighted clinical development progress and provided guidance on upcoming data releases for simufilam, the company's lead drug candidate to treat Alzheimer's disease.

Cassava Sciences is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!